Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada
Sonoma Pharmaceuticals (NASDAQ:SNOA) has expanded its partnership with a leading global healthcare distributor for marketing and distributing its wound care products in Canada. This amendment to their existing agreement, which previously covered distribution in the United States, now includes over-the-counter wound care products for sale in both countries.
The expanded partnership aims to bring Sonoma's Microcyn® technology based stabilized hypochlorous acid (HOCl) products to Canadian patients, offering improved management of acute and chronic wounds. CEO Amy Trombly highlighted the distributor's expertise and network as key factors in reaching new patients and providing greater accessibility to consumers through over-the-counter products.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha espanso la sua partnership con un importante distributore globale di healthcare per la commercializzazione e distribuzione dei suoi prodotti per la cura delle ferite in Canada. Questa modifica al loro accordo esistente, che in precedenza copriva la distribuzione negli Stati Uniti, ora include prodotti per la cura delle ferite da banco disponibili in entrambi i paesi.
La partnership ampliata mira a portare ai pazienti canadesi i prodotti a base della tecnologia Microcyn®, un acido ipocloroso stabilizzato (HOCl) per una migliore gestione delle ferite acute e croniche. La CEO Amy Trombly ha sottolineato che l'esperienza e la rete del distributore sono fattori chiave per raggiungere nuovi pazienti e fornire una maggiore accessibilità ai consumatori tramite prodotti da banco.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha ampliado su asociación con un importante distribuidor global de atención médica para el marketing y distribución de sus productos para el cuidado de heridas en Canadá. Esta modificación a su acuerdo existente, que anteriormente cubría la distribución en los Estados Unidos, ahora incluye productos de cuidado de heridas de venta libre para su venta en ambos países.
La asociación ampliada tiene como objetivo llevar la tecnología Microcyn® de productos basados en ácido hipocloroso estabilizado (HOCl) a los pacientes canadienses, ofreciendo una mejor gestión de heridas agudas y crónicas. La CEO Amy Trombly destacó que la experiencia y la red del distribuidor son factores clave para alcanzar nuevos pacientes y proporcionar una mayor accesibilidad a los consumidores a través de productos de venta libre.
소노마 제약(Sonoma Pharmaceuticals, NASDAQ:SNOA)은 파트너십을 확장했습니다 글로벌 헬스케어 유통업체와 함께 캐나다에서 자사의 상처 치료 제품 마케팅 및 배급을 위해. 이 기존 계약의 수정은 이전에 미국 내 배급을 포함하고 있었으며, 이제 두 나라에서 판매되는 약국에서 구입할 수 있는 상처 관리 제품들을 포함합니다.
확대된 파트너십은 소노마의 Microcyn® 기술에 기반한 안정화된 차아염소산(HOCl) 제품을 캐나다 환자에게 제공하여 급성 및 만성 상처 관리를 개선하는 것을 목표로 하고 있습니다. CEO 에이미 트롬블리는 배급업체의 전문성과 네트워크가 새로운 환자에게 도달하고 약국 제품을 통해 소비자에게 더 큰 접근성을 제공하는 데 핵심적인 요소라고 강조했습니다.
Sonoma Pharmaceuticals (NASDAQ:SNOA) a élargi son partenariat avec un distributeur mondial de soins de santé de premier plan pour le marketing et la distribution de ses produits de soin des plaies au Canada. Cet amendement à leur accord existant, qui couvrait précédemment la distribution aux États-Unis, inclut désormais des produits de soin des plaies en vente libre à vendre dans les deux pays.
Le partenariat élargi vise à apporter aux patients canadiens des produits à base de technologie Microcyn®, une solution stabilisée d'acide hypochloreux (HOCl), offrant une meilleure prise en charge des plaies aiguës et chroniques. La PDG Amy Trombly a souligné que l'expertise et le réseau du distributeur sont des facteurs clés pour atteindre de nouveaux patients et offrir un meilleur accès aux consommateurs grâce aux produits en vente libre.
Sonoma Pharmaceuticals (NASDAQ:SNOA) hat seine Partnerschaft erweitert mit einem führenden globalen Gesundheitsdistributor für Marketing und Vertrieb seiner Wundversorgung Produkte in Kanada. Diese Änderung ihrer bestehenden Vereinbarung, die zuvor die Verteilung in den Vereinigten Staaten umfasste, beinhaltet jetzt auch verschreibungspflichtfreie Wundversorgung Produkte, die in beiden Ländern verkauft werden können.
Die erweiterte Partnerschaft zielt darauf ab, Sonomas Microcyn® Technologie basierte stabilisierte hypochlorige Säure (HOCl) Produkte zu kanadischen Patienten zu bringen und eine verbesserte Behandlung von akuten und chronischen Wunden anzubieten. CEO Amy Trombly betonte, dass das Fachwissen und das Netzwerk des Distributors entscheidende Faktoren sind, um neue Patienten zu erreichen und den Verbrauchern über rezeptfreie Produkte einen besseren Zugang zu ermöglichen.
- Expanded distribution agreement to include Canadian market
- Addition of over-the-counter wound care products for sale in US and Canada
- Potential for increased market reach and product accessibility
- None.
Insights
The expanded distribution agreement for Sonoma Pharmaceuticals' wound care products in Canada represents a significant market opportunity. Canada's healthcare market, valued at over
However, it's important to note that Sonoma is a micro-cap company with a market capitalization of just over
Sonoma's Microcyn technology, based on stabilized hypochlorous acid (HOCl), has shown promising results in wound care applications. Its ability to reduce pain, itch and scarring while promoting healing addresses key patient needs in both acute and chronic wound management. The expansion into Canada's healthcare system could provide valuable clinical data and user feedback, potentially strengthening Sonoma's position in the competitive wound care market.
The addition of over-the-counter products is particularly intriguing, as it opens up a broader consumer market. This move aligns with the growing trend of self-care and home healthcare management. However, success in this space will depend on effective marketing, competitive pricing and clear demonstration of product efficacy compared to established brands.
BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into an amendment to its distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in Canada.
As previously announced, on August 19, 2024, Sonoma entered into a distribution agreement with a global healthcare distributor for the marketing and distribution of its wound care products in the United States, to be sold through hospital systems and other healthcare channels. The new amendment allows the same distributor to also distribute these products in Canada, and adds over-the-counter wound care products for sale in both countries.
"This expanded partnership with a global healthcare distributor will enable us to bring our wound care products and the regenerative power of Microcyn technology to Canada," said Amy Trombly, CEO of Sonoma. "Our distributor's expertise and distribution network will allow new patients in Canada the opportunity to benefit from improved management of both acute and chronic wounds, reduction in pain, itch and scarring, and the peace of mind that results from Sonoma's safe and effective technology. We are also pleased that our distributor plans to sell over-the-counter products as well, allowing consumers to benefit from greater accessibility of our wound care products."
Further information about the amendment can be found in the Current Report on Form 8-K filed by Sonoma with the U.S. Securities and Exchange Commission on October 22, 2024.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What new market has Sonoma Pharmaceuticals (SNOA) expanded into for its wound care products?
What new product category has been added to Sonoma Pharmaceuticals' (SNOA) distribution agreement?
When did Sonoma Pharmaceuticals (SNOA) announce its expanded partnership for Canadian distribution?
What technology is the basis for Sonoma Pharmaceuticals' (SNOA) wound care products?
